ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
ARROWHEAD PHARMACEUTICALS, INC.
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$57.23+1.33 (+2.38%)
Close on Oct 19, 2026
- Market cap
- $8.21B
- P/E (TTM)
- –
- Dividend yield
- –
Arrowhead Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $8.08B | $164.85M |
| Enterprise Value | $6.48B | $87.06M |
| PS Ratio | 12.07 | 3.60 |
| PB Ratio | 17.37 | 2.03 |
| P/TBV Ratio | 17.58 | 2.31 |
Enterprise value
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 9.68 | 2.43 |
Income (trailing twelve months)
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $669.50M | $57.94M |
| Operating Income | -$226.44M | -$21.44M |
| Pretax Income | -$252.08M | -$14.45M |
| Net Income | -$319.95M | -$22.46M |
| EBITDA | -$202.34M | -$16.91M |
| EPS (Diluted) | -$2.25 | -$0.83 |
Margins
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -33.8% | -44.5% |
| Pretax Margin | -37.7% | -13.0% |
| Profit Margin | -47.8% | -39.2% |
| EBITDA Margin | -30.2% | -31.3% |
| FCF Margin | -11.2% | -8.85% |
Returns
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -64.8% | -53.1% |
| Return on Assets (ROA) | -18.3% | -41.0% |
| Return on Capital Employed (ROCE) | -12.4% | -37.8% |
Growth
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 16.8% | 6.01% |
| Revenue Growth (3Y CAGR) | 50.5% | 2.25% |
| Revenue Growth (5Y CAGR) | 56.6% | 6.42% |
Balance sheet
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.60B | $62.42M |
| Net Cash (Debt) | $1.60B | $15.68M |
| Net Cash Per Share | $11.34 | $0.66 |
| Equity (Book Value) | $465.53M | $48.79M |
| Book Value Per Share | $3.30 | $1.36 |
| Tangible Book Value | $459.94M | $23.06M |
| Working Capital | $1.39B | $75.77M |
Financial position
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 5.90 | 3.30 |
| Quick Ratio | 5.68 | 2.39 |
| Interest Coverage | -2.45 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$59.06M | -$12.35M |
| Capital Expenditures | -$16.06M | -$1.06M |
| Free Cash Flow | -$75.11M | -$20.28M |
| FCF Per Share | -$0.53 | -$0.42 |
Efficiency
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 0.38 | 0.38 |
| Revenue Per Employee | $941.62K | $398.96K |
| Profits Per Employee | -$450.00K | -$703.34K |
| Employee Count | 711 | 74 |
Dividends and yields
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -3.96% | -22.7% |
| FCF Yield | -0.93% | -9.07% |
Shares
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 141,254,000 | 58,179,650 |
| Shares Change (YoY) | 7.41% | 11.1% |
| Shares Change (QoQ) | 0.40% | 0.54% |
| Float | 135,559,000 | 49,173,100 |
| Shares Held by Insiders | 4.03% | 11.6% |
| Shares Held by Institutions | 84.6% | 59.4% |
Taxes
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $20.05M | $91.50K |
Scores
| Measure | Arrowhead Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 2.42 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Arrowhead Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.